RegeneRx is developing RGN-352, an injectable Tβ4 formulation for the treatment of systemic tissue and organ damage including cardiac, nervous system, pulmonary and kidney pathologies. Numerous animal models of cardiac injury have shown the effectiveness of RGN-352 in reducing scar volume, in increasing cardiac function, and in survival. Preclinical studies have identified Tβ4’s ability to recruit stem cells and stimulate differentiation, reduce apoptosis and inflammation, protect cells from cytotoxicity, increase angiogenesis and reduce scar formation in animal models. Based on work in animal models, recently published scientifc papers have suggested that Tβ4 could prevent or reduce damage to the lungs and kidneys is patients with systemic inflammatory response syndrome (SIRS) and sepsis, as well as in COVID patients.
The following observations of Tβ4’s effects on myocardial infarction and chronic heart failure in a variety of animal models have been published in major high-impact scientific journals and underlie the rationale for evaluating RGN-352 in MI and heart failure patients:
CNS AND PNS DISORDERS
Preclinical data support potent regenerative/protective effects and dose responses of Tβ4 on the peripheral and central nervous systems. For reasons listed above, Tβ4 has significant potential for the treatment of various neurological injuries such as traumatic brain injury, stroke, peripheral neuropathy, multiple sclerosis, spinal cord injury, etc. As with myocardial studies, Tβ4 has been shown to promote tissue repair/regeneration in numerous CNS and PNS animal models:
Traumatic brain injury
Spinal cord injury
RegeneRx successfully completed a Phase 1 clinical trial in 80 healthy subjects using an acute dosing regimen. RGN-352 was shown to be safe and well-tolerated at 4 dose levels. RegeneRx has also successfully completed a $3 million grant from the National Heart, Lung, and Blood Institute of the NIH to conduct a number of additional animal toxicology and pharmacokinetics studies to support human clinical trials.
To date, over 1700 patients have been tested with RegeneRx’s Tβ4-based product formulations administered topically to the skin, the eye, and injected into the blood stream. The formulations have produced no serious adverse events and have been deemed to be safe and well-tolerated in every clinical study to date. We believe RGN-352 is now ready for Phase 2 clinical trials in the acute setting.